Use of the MitraClip as a bridge strategy to heart transplantation was safe, with two-thirds of patients free from adverse events at one year, according to findings from the MitraBridge study presented Oct. 16 during TCT 2020.

Cosmo Godino, MD, et al., evaluated data from 119 patients in the International MitraBridge Registry. The median age of patients was 58 and all had moderate to severe, or severe secondary, mitral regurgitation and advanced heart failure. Patients were treated with the MitraClip as a bridge strategy based on the following criteria: active on the heart transplantation list (N=32); suitable for heart transplantation but awaiting clinical decision (N=54); or not yet suitable for heart transplantation because of potentially reversible relative contraindications (N=34).

Overall results showed procedural success was achieved in 87.5% of cases, and 30-day survival was 100%. Godino and colleagues also noted at the time of last available follow-up (median: 532 days), 15% of patients underwent elective transplant; 15.5% remained or could be included in the heart transplantation waiting list; and 23.5% no longer had an indication for heart transplantation due to clinical improvement.

“These findings should be considered exploratory and hypothesis-generating to guide further study for percutaneous intervention in high-risk patients with advanced heart failure,” said Godino, et al. The study was simultaneously published in the Journal of Heart and Lung Transplantation.

Clinical Topics: Cardiac Surgery, Invasive Cardiovascular Angiography and Intervention, Valvular Heart Disease, Aortic Surgery, Cardiac Surgery and Heart Failure, Cardiac Surgery and VHD, Heart Transplant, Interventions and Structural Heart Disease, Mitral Regurgitation

Keywords: TCT20, Transcatheter Cardiovascular Therapeutics, Percutaneous Coronary Intervention, Heart Transplantation, Mitral Valve Insufficiency

< Back to Listings